바로가기
메인메뉴로 바로가기
콘텐츠 바로가기
하단메뉴로 바로가기
패밀리사이트 바로가기


진료과

  • 연세암병원-종양내과, 두경부암센터, 식도암센터, 폐암센터

전문진료분야

  • <종양내과> 폐암, 두경부암, 식도암, 항암약물치료, 신약치료 *해외 연구출장中: 2019.3.1~2020.2.20

교육 및 임상 경력

  • 2005-2006  세브란스병원  인턴  수료 
  • 2006-2010  세브란스병원  내과  레지던트  수료 
  • 2010-2012  세브란스  병원  연세  암센터  종양내과  임상강사   
  • 2012-2016  세브란스  병원  연세  암센터  종양내과  임상조교수
  • 2016-현  재  세브란스  병원  연세  암병원  종양내과  조교수

학술관련경력

  • 2012. 5 한국임상암학회 보령학술상 수상
  • 2012. 5 한국임상암학회 APJCO 논문상 수상
  • 2012. 7 보건장학회 학술 연구비 수상
  • 2012.11 한국임상암학회 한미연제 발표 우수상

주요 관심분야

학력사항

  • 연세대학교 의과대학 의학과 학사 (2005)
  • 연세대학교 의과대학 의학과 석사 (2010)
  • 연세대학교 의과대학 의학과 박사 (2015)

논문

  • 1. Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma
  • H. R. Kim, S. Y. Rha, S. H. Cheon, J. K. Roh, Y. N. Park & N. C. Yoo
  • Annals of Oncology 20: 780?787, 2009
  • 2. Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma
  • HYE RYUN KIM, SEONG HA CHEON, KWANG-HUN LEE, JUNG RYUN AHN,HEI-CHEUL JEUNG SUNG SOOK LEE, HYUN CHEOL CHUNG,SUNG HOON NOH, & SUN YOUNG RHA
  • Int. J. Hyperthermia, 2010, 1?11
  • 3. Tension pneumopericardium after removal of pericardiocentesis drainage catheter
  • Hye Ryun Kim, Donghoon Choi, Joo Won Chung, Young Nam Youn, Chi Young Shim
  • Cardiology Journal 2009, Vol. 16, No. 5, pp. 477?.478
  • 4. A Case of Henoch-Shonlein Purpura Caused by Rifampin
  • Hye Ryun Kim, Byung Hoon Park, Ji Young Sohn, Ji Ye Chung, Jung Ryun Ahn, Yoon Suk Jeung, Joo Eun Yim, Joo Won Cheung, Jiye Moon, Moo Suk Park
  • Tuberculosus and Respiratory Disease August, 2008 Vol 65, No 2
  • Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
    LUNG CANCER 136/ :30-36,2019
  • Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
    ANNALS OF ONCOLOGY 30/7 :1,104-1,113,2019
  • Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 84/2 :405-414,2019
  • A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.
    LUNG CANCER 134/ :46-51,2019
  • Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
    CANCER RESEARCH AND TREATMENT 51/1 :300-312,2019
  • A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First
    CANCER RESEARCH AND TREATMENT 51/2 :718-726,2019
  • Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 145/6 :1,613-1,623,2019
  • YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-smallcell lung cancer
    CLINICAL CANCER RESEARCH 25/8 :2,575-2,587,2019
  • TRIUMPH Trial: One Small Step Could Become One Giant Leap for Precision Oncology in Head and Neck Cancer.
    CANCER RESEARCH AND TREATMENT 51/1 :413-414,2019
  • Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma.
    LUNG CANCER 131/ :139-146,2019
  • Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
    YONSEI MEDICAL JOURNAL 60/6 :525-534,2019
  • Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate
    PLOS ONE 14/3 :e0214291-,2019
  • The Ratio of Peripheral Regulatory T Cells to Lox-11 Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti?PD-1 Therapy in Patients with Non?Small Cell Lung Cancer
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 199/2 :243-246,2019
  • Brigatinib versus Crizotinib in ALK-Positive Non?Small-Cell Lung Cancer
    NEW ENGLAND JOURNAL OF MEDICINE 379/21 :2,027-2,039,2018
  • ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    ONCOGENE 37/3 :377-388,2018
  • Survival and Functional Outcome after Treatment for Primary Base of Tongue Cancer: A Comparison of Definitive Chemoradiotherapy versus Surgery Followed by Adjuvant Radiotherapy
    CANCER RESEARCH AND TREATMENT 50/4 :1,214-1,225,2018
  • Characteristics and Outcome of ROS1-Positive Non?Small Cell Lung Cancer Patients in Routine Clinical Practice
    JOURNAL OF THORACIC ONCOLOGY 13/9 :1,373-1,382,2018
  • Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.
    CANCER RESEARCH 78/12 :3,350-3,362,2018
  • Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    LUNG CANCER 124/ :168-178,2018
  • Radon Exposure-induced Genetic Variations in Lung Cancers among Never Smokers
    JOURNAL OF KOREAN MEDICAL SCIENCE 33/29 :e207-e216,2018
  • Effects of Serum Albumin, Calcium Levels, Cancer Stage and Performance Status on Weight Loss in Parathyroid Hormone-Related Peptide Positive or Negative Patients with Cancer
    대한내분비학회지 33/1 :97-104,2018
  • A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer
    ANNALS OF SURGICAL ONCOLOGY 25/4 :864-871,2018
  • The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control.
    CANCER NURSING 41/2 :49-57,2018
  • Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 40/1 :55-62,2018
  • Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH 10/5 :593-603,2017
  • Novel Genetic Associations Between Lung Cancer and Indoor Radon Exposure
    Journal of Cancer Prevention 22/4 :234-240,2017
  • Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    LANCET RESPIRATORY MEDICINE 5/11 :891-902,2017
  • Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization.
    ONCOTARGET 8/50 :87,234-87,243,2017
  • Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinoma
    ORAL ONCOLOGY 75/ :16-21,2017
  • Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma
    APMIS 125/11 :974-984,2017
  • Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis.
    ONCOTARGET 8/39 :65,111-65,122,2017
  • Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs
    LUNG CANCER 113/0 :106-114,2017
  • A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
    ONCOTARGET 8/9 :15,943-15,951,2017
  • Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer
    LUNG CANCER 111/ :79-83,2017
  • Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
    JOURNAL OF CLINICAL ONCOLOGY 35/23 :2,613-2,618,2017
  • Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
    NEW ENGLAND JOURNAL OF MEDICINE 376/7 :629-640,2017
  • Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)
    CANCER 123/11 :1,958-1,964,2017
  • Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer
    LUNG CANCER 105/ :17-22,2017
  • Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of nonsmall-cell lung cancer
    JOURNAL OF NEURO-ONCOLOGY 132/2 :333-340,2017
  • Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
    ANNALS OF ONCOLOGY 28/6 :1,250-1,259,2017
  • Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study
    Radiation Oncology Journal 35/2 :153-162,2017
  • Prevalence and prognostic implications of psychological distress in patients with gastric cancer
    BMC CANCER 17/1 :283-,2017
  • Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non?Small Cell Lung Cancer
    JOURNAL OF THORACIC ONCOLOGY 12/3 :491-500,2017
  • EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines
    MOLECULAR CANCER THERAPEUTICS 15/7 :1,627-1,636,2016
  • Clinical course of stage IV invasive mucinous adenocarcinoma of the lung
    LUNG CANCER 102/ :82-88,2016
  • PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
    SCIENTIFIC REPORTS 6/36956 :1-12,2016
  • Alteration status and prognostic value of MET in head and neck squamous cell carcinoma
    JOURNAL OF CANCER 7/15 :2,197-2,206,2016
  • Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
    ONCOTARGET 7/6 :6,984-6,993,2016
  • Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution
    PLOS ONE 11/4 :e0154133-,2016
  • Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    JOURNAL OF TRANSLATIONAL MEDICINE 14/1 :296-,2016
  • Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 38/Suppl :E1,653-E1,659,2016
  • Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
    ONCOTARGET 7/9 :10,547-10,556,2016
  • A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 77/3 :539-548,2016
  • Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
    ONCOTARGET 7/17 :24,172-24,178,2016
  • ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models
    LUNG CANCER 95/ :57-64,2016
  • Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
    ONCOTARGET 7/24 :36,311-36,320,2016
  • Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study
    CANCER 122/19 :3,024-3,031,2016
  • Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.
    Oncogenesis 5/7 :e241-,2016
  • PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma
    ONCOTARGET 7/21 :30691-30701,2016
  • Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status
    LUNG CANCER 97/ :73-80,2016
  • Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy
    ONCOLOGY 90/5 :248-254,2016
  • A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib
    JOURNAL OF THORACIC ONCOLOGY 11/5 :e55-e58,2016
  • Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck
    SCIENTIFIC REPORTS 6/ :19552-,2016
  • Serum PTHrP predicts weight loss in cancer patients independent of hypercalcemia, inflammation, and tumor burden
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM 101/3 :1207-1214,2016
  • Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Lung Adenocarcinoma: Early Response and Dosimetric Evaluation.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT 15/1 :122-129,2016
  • Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy
    PHARMACOGENETICS AND GENOMICS 26/3 :116-125,2016
  • Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
    ONCOTARGET 6/42 :44971-44984,2015
  • Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells
    LUNG CANCER 90/2 :175-181,2015
  • PD-1: Dual guard for immunopathology
    ONCOTARGET 6/26 :21783-21784,2015
  • Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
    MOLECULAR CANCER THERAPEUTICS 14/10 :2238-2248,2015
  • Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
    CANCER RESEARCH AND TREATMENT 74/4 :781-789,2015
  • The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer
    ANNALS OF SURGICAL ONCOLOGY 22/12 :3938-3945,2015
  • An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
    EUROPEAN JOURNAL OF CANCER 51/12 :1588-1595,2015
  • The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer
    LUNG CANCER 88/3 :325-331,2015
  • Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma
    ONCOTARGET 6/4 :2562-2572,2015
  • Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
    CLINICAL CANCER RESEARCH 21/3 :544-552,2015
  • Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency
    EUROPEAN JOURNAL OF CANCER 50/4 :746-752,2014
  • Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements
    PLOS ONE 9/Issue 7 :e103333-,2014
  • Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
    GENOME MEDICINE 6/18 :1-10,2014
  • Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations
    LUNG CANCER 84/2 :196-202,2014
  • Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma
    LUNG CANCER 83/3 :389-395,2014
  • A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 73/4 :665-671,2014
  • Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma
    LUNG CANCER 83/3 :374-382,2014
  • Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 72/ :825-835,2013
  • EGFR and TTF-1 Gene Amplification in Surgically Resected Lung Adenocarcinomas: Clinicopathologic Significance and Effect on Response to EGFR-Tyrosine Kinase Inhibitors in Recurred Cases
    ANNALS OF SURGICAL ONCOLOGY 20/9 :3015-3022,2013
  • The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
    ANNALS OF ONCOLOGY 24/9 :2364-2370,2013
  • Multicentre phase II trial of bevacizumab combined with docetaxel?-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
    ANNALS OF ONCOLOGY 24/6 :1485-1490,2013
  • Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer
    LUNG CANCER 80/3 :313-318,2013
  • The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma
    YONSEI MEDICAL JOURNAL 54/4 :865-874,2013
  • Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.
    FUTURE ONCOLOGY 9/3 :377-386,2013
  • Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer.
    JOURNAL OF CLINICAL ONCOLOGY 31/6 :731-737,2013
  • A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)
    LUNG CANCER 79/3 :270-275,2013
  • Phase II Study of Cisplatin with Irinotecan as Induction Chemotherapy Followed by Chemoradiotherapy for Unresectable Stage III Non-small Cell Lung Cancer
    ANTICANCER RESEARCH 32/8 :3515-3521,2012
  • The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 70/4 :539-546,2012
  • A phase i pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
    INVESTIGATIONAL NEW DRUGS 30/4 :1501-1510,2012
  • A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy
    INVESTIGATIONAL NEW DRUGS 30/ :672-680,2012
  • Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
    CANCER 118/3 :729-739,2012
  • Efficacy of Oxaliplatin-Based Chemotherapy in Curatively Resected Colorectal Cancer with Liver Metastasis
    ONCOLOGY 81/3-4 :175-183,2011
  • Treatment of recurrent hepatocellular carcinoma after liver transplantation
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 7/3 :258-269,2011
  • Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma
    International Journal Of Hyperthermia 26/4 :305-315,2010
  • Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials
    Cancer Research And Treatment 41/4 :196-204,2009
  • Tension pneumopericardium after removal of pericardiocentesis drainage catheter
    Cardiology Journal 16/5 :477-478,2009
  • Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma
    Annals Of Oncology 20/4 :780-787,2009
  • clinical value of ezrin expression in primary osteosarcoma
    Cancer Research And Treatment 41/3 :138-144,2009
  • Prognosis of pN3 stage gastric cancer
    Cancer Research And Treatment 41/2 :73-79,2009
  • 선천성 간경변증에서 발생한 국소결절증식양 결절 1예
    대한내과학회지 76/ :s26-s30,2009
  • 결핵 환자에서 Rifampin에 의한 Henoch-Sh?nlein Purpura 1예
    Tuberculosis and Respiratory Diseases(결핵 및 호흡기질환) 65/2 :116-120,2008
  • Transthoracic Echocardiographic Detection, Differential Diagnosis, and Follow-Up of Esophageal Hematoma
    Korean Circulation Journal 37/12 :666-670,2007

김혜련

콘텐츠 처음으로 이동

네크워크 링크안내/사이트 정보